Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Rui‐Hua Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9771-8534; OpenAlex author ID A5101613292. Sources: ClinicalTrials.gov.

Their work

Papers
17 (first author 1, last author 11)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
71
Papers, trials and grants by year

2012: 3 papers · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 3 papers · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 1 trial · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 trial · 2025: 2 papers · 2026: 1 paper

Papers 17

  1. Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer. Last author DOI 10.1038/s41416-025-03286-w↗
  2. Corrigendum to "Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer [Cancer Lett. 379 (2016) 1-11]. Last author DOI 10.1016/j.canlet.2025.217562↗
  3. Development and validation of a nomogram to predict overall survival in elderly patients with pancreatic cancer without surgical treatment. First author DOI 10.1097/md.0000000000045474↗
  4. Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. Co-author DOI 10.1200/jco.22.02630↗
  5. Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Co-author DOI 10.1038/s41467-019-09712-x↗
  6. Combined Analysis of the Aberrant Epigenetic Alteration of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2019/9379864↗
  7. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Co-author DOI 10.1186/s40880-019-0367-7↗
  8. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ncomms14437↗
  9. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. Last author DOI 10.1016/j.canlet.2016.05.024↗
  10. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation. Last author DOI 10.1111/jpi.12285↗
  11. Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value. Last author DOI 10.7150/jca.14185↗
  12. Reduced expression of p21-activated protein kinase 1 correlates with poor histological differentiation in pancreatic cancer. Last author DOI 10.1186/1471-2407-14-650↗
  13. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Last author DOI 10.1007/s00280-013-2102-4↗
  14. The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. Last author DOI 10.1186/1479-5876-11-249↗
  15. ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. Last author DOI 10.1002/ijc.26376↗
  16. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Last author DOI 10.1007/s12032-012-0226-8↗
  17. Are risk factors associated with outcomes in pancreatic cancer? Last author DOI 10.1371/journal.pone.0041984↗

Trials 2

  1. A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors Principal investigator NCT06500052↗
  2. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 Principal investigator NCT04805307↗

Closest collaborators

The 25 strongest of 71 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Feng Wang · 2 shared papers, 1 shared trial, 2013–2024 · strength 0.75
  2. Huai‐Qiang Ju · 4 shared papers, 2016–2025 · strength 0.40
  3. Paul J. Chiao · 4 shared papers, 2016–2025 · strength 0.40
  4. Yun‐Xin Lu · 3 shared papers, 2016–2025 · strength 0.35
  5. Jing Yan · 1 shared paper, 2025 · strength 0.33
  6. Haifeng Zhang · 1 shared paper, 2025 · strength 0.33
  7. Kang Li · 1 shared paper, 2025 · strength 0.33
  8. De‐Shen Wang · 7 shared papers, 2012–2019 · strength 0.30
  9. Xinfang Hou · 1 shared paper, 2026 · strength 0.24
  10. Jianzhen Shan · 1 shared paper, 2026 · strength 0.24
  11. Noboru Yamamoto · 1 shared paper, 2026 · strength 0.24
  12. Dong Yan · 1 shared paper, 2026 · strength 0.24
  13. Vinod Ganju · 1 shared paper, 2026 · strength 0.24
  14. Yuhong Li · 5 shared papers, 2012–2019 · strength 0.23
  15. Feng‐Hua Wang · 4 shared papers, 2012–2019 · strength 0.20
  16. Miao‐Zhen Qiu · 5 shared papers, 2012–2016 · strength 0.18
  17. Dong-sheng Zhang · 4 shared papers, 2012–2013 · strength 0.13
  18. Chunyi Hao · 1 shared paper, 2023 · strength 0.13
  19. Ying Yuan · 1 shared paper, 2023 · strength 0.13
  20. Hongmei Zhang · 1 shared paper, 2023 · strength 0.13
  21. Lin Yang · 1 shared paper, 2023 · strength 0.13
  22. Lin Shen · 1 shared paper, 2023 · strength 0.13
  23. Jianming Xu · 1 shared paper, 2023 · strength 0.13
  24. Qingshan Zheng · 1 shared paper, 2023 · strength 0.13
  25. Jin Li · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.